Clinical Trials Browser

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05541016 2026-05-12

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Phase 2 Recruiting

455 enrolled

Head & Neck

Carcinoma, Oropharyngeal Neoplasms

NCT06445114 2026-05-08

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

Phase 2 Recruiting

50 enrolled

Head & Neck

Carcinoma, Oropharyngeal Neoplasms

NCT04116047 2026-05-07

CompARE

Phase 3 Active not recruiting

785 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT05050162 2026-05-07

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Phase 2/3 Suspended

1,714 enrolled

Head & Neck

Carcinoma, Oropharyngeal Neoplasms

NCT05721755 2026-05-05

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 3 Active not recruiting

290 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03952585 2026-05-04

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Phase 2/3 Active not recruiting

384 enrolled 22 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

NCT06532279 2026-05-04

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Phase 2 Recruiting

98 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

Clinical Trials

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

ARTHOUSE

MINT-2

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

CompARE

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer